科研成果：科学论文与知识产权

专注给予质高价优

的生物药

科学论文

Liu Y, Wang Y, Zhu Y, et al. HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 study. Cancer Commun (Lond). 2024 Dec;44(12):1431-1443. doi: 10.1002/cac2.12621. Epub 2024 Oct 24. PMID: 39446605; PMCID: PMC11666995.
Cancer Communications
Phase II study of pyrotinib plus albumin-bound paclitaxel and Trastuzumab (HLX02) as neoadjuvant treatment in HER2-positive, stage II-III breast cancer
ESMO 2024
Exploratory Biomarker Analysis of the Phase 3 ASTRUM-005 Study: Serplulimab Versus Placebo Plus Chemotherapy for Extensive-stage Small Cell Lung Cancer
AACR 2024
Safety, Preliminary Efficacy, and Pharmacokinetics of HLX26 plus Serplulimab in Advanced Solid Tumours: an Open-label, Dose-escalation Phase 1 Study
ESMO Asia 2023
A phase 2 study of HLX208, a BRAFV600E inhibitor, in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harboring BRAFV600E mutation.
ASCO 2023
HLX208, a novel BRAF V600E inhibitor, in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harbouring BRAF V600E mutation
ESMO Asia 2023

知识产权

专利申请数量	PCT申请数量	国内外授权专利数量	注册司法权区	申请日期	到期日	发明专利数量
809	90	134	中国大陆	2011-03-18	2031-03-18	97

OB视讯(中国)